Last reviewed · How we verify
anti IL5 receptor antibodies
anti IL5 receptor antibodies is a IL-5 receptor antagonist monoclonal antibody Biologic drug developed by Scarlata, Simone, M.D.. It is currently FDA-approved for Eosinophilic asthma, Chronic rhinosinusitis with nasal polyps, Eosinophilic granulomatosis with polyangiitis (EGPA).
Anti-IL-5 receptor antibodies block the interleukin-5 receptor on eosinophils, preventing eosinophil activation and reducing eosinophilic inflammation.
Anti-IL-5 receptor antibodies block the interleukin-5 receptor on eosinophils, preventing eosinophil activation and reducing eosinophilic inflammation. Used for Eosinophilic asthma, Chronic rhinosinusitis with nasal polyps, Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | anti IL5 receptor antibodies |
|---|---|
| Sponsor | Scarlata, Simone, M.D. |
| Drug class | IL-5 receptor antagonist monoclonal antibody |
| Target | IL-5 receptor (IL-5R) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
These monoclonal antibodies bind to the IL-5 receptor (IL-5R) on the surface of eosinophils and their precursors, blocking the signaling pathway that promotes eosinophil survival, activation, and recruitment. By inhibiting IL-5 signaling, these antibodies reduce circulating and tissue eosinophil counts, thereby suppressing eosinophil-mediated inflammatory responses in conditions characterized by eosinophilic inflammation.
Approved indications
- Eosinophilic asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Headache
- Injection site reactions
- Upper respiratory tract infections
- Arthralgia
Key clinical trials
- Benralizumab in the Treatment of Patients With Severe Asthma With ABPA (PHASE4)
- Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients. (PHASE4)
- A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563). (PHASE2)
- Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
- A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma (PHASE2)
- A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti IL5 receptor antibodies CI brief — competitive landscape report
- anti IL5 receptor antibodies updates RSS · CI watch RSS
- Scarlata, Simone, M.D. portfolio CI
Frequently asked questions about anti IL5 receptor antibodies
What is anti IL5 receptor antibodies?
How does anti IL5 receptor antibodies work?
What is anti IL5 receptor antibodies used for?
Who makes anti IL5 receptor antibodies?
What drug class is anti IL5 receptor antibodies in?
What development phase is anti IL5 receptor antibodies in?
What are the side effects of anti IL5 receptor antibodies?
What does anti IL5 receptor antibodies target?
Related
- Drug class: All IL-5 receptor antagonist monoclonal antibody drugs
- Target: All drugs targeting IL-5 receptor (IL-5R)
- Manufacturer: Scarlata, Simone, M.D. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Eosinophilic asthma
- Indication: Drugs for Chronic rhinosinusitis with nasal polyps
- Indication: Drugs for Eosinophilic granulomatosis with polyangiitis (EGPA)
- Compare: anti IL5 receptor antibodies vs similar drugs
- Pricing: anti IL5 receptor antibodies cost, discount & access